We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Efmody

News List

MHRA authorises Diurnal’s CAH therapy Efmody pharmatimes
July 02, 2021
Speciality pharma company Diurnal announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Efmody a marketing authorisation in Great Britain.
EC authorises Diurnal’s Efmody for CAH pharmatimes
June 02, 2021
The European Commission (EC) has approved UK-headquartered pharma company Diurnal’s Efmody for the treatment of congenital adrenal hyperplasia (CAH).
Five new meds recommended in March CHMP decisions pharmatimes
March 30, 2021
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended five new medicines for approval at its March meeting, as well as six recommendations of current indications.